Navigation Links
Genetic Engineering & Biotechnology News reports on cancer biomarkers
Date:4/1/2008

New Rochelle, NY, April 1, 2008Biotechnology companies are focusing on the development of novel biomarkers to overcome the limitations of current diagnostic tests for cancer, reports Genetic Engineering and Biotechnology News (GEN). To effectively move cancer therapy forward, a much stronger and targeted emphasis on diagnosis will be required, according to an article in the April 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2428).

"Therapeutic protocols can involve hundreds of thousands of dollars per cancer patient," notes John Sterling, Editor-in-Chief of GEN (www.genengnews). "Coming up with effective and validated biomarkers that detect cancer while still in its early stages seems like an extremely worthwhile effort on which to spend R&D funds now to cut down on costs of treatment in the future."

A team led by Edouard Nice, Ph.D., at the Ludwig Institute for Cancer Research, is one example of a group hard at work trying to develop early detection tools for malignancies. Dr. Nice and his colleagues are using multidimensional high-performance liquid chromatography to trace enrich low-level components such as growth factors in tumor material prior to analysis by mass spectrometry.

At Wayne State University School of Medicine, a research program run by Michael Tainsky, Ph.D., harnesses antibodies in patients' serum for the detection of cancer-specific epitopes using peptides selected for IgG binding from phage-display cDNA libraries.

Other biomarker-related projects covered in the GEN article include those at Sienna Cancer Diagnostics, Geron, Quest Diagnostics Nichols Institute, Gentel Biosciences, Celera, University of Washington, Abbott Laboratories, Strategic Diagnostics, Plasma Proteome Institute, and Biosite.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology technology :

1. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
2. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. Interleukin Genetics Retains Top Life Science Communications Firms
5. On the trail of rogue genetically modified pathogens
6. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. deCODE Genetics Announces Full-year 2007 Financial Results
8. Genetic manipulation might model cystic fibrosis
9. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
10. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
11. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):